Keywords: Bristol-Myers Squibb, Innate Pharma, Cancer antibody, IPH2102, Licensing

Bristol-Myers Squibb in up to $465 million deal with Innate Pharma for cancer antibody

Article | 07 July 2011

Print This

US drug major Bristol-Myers Squibb (NYSE: BMY) has signed a global agreement with French biotech firm Innate Pharma (Euronext Paris: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in